PolyPeptide Group AG

PPGN

CH1110760852

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:57 2024-04-25 am EDT			5-day change	1st Jan Change
28.85 ^CHF	-1.87%		-1.20%	+64.67%

Mar. 12	PolyPeptide Group AG Provides Earnings Guidance for 2024	CI
Mar. 12	Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024

PolyPeptide Group AG Appoints Peter Wilden as Executive Chairman

January 30, 2023 at 12:09 pm EST

PolyPeptide Group AG announced that Dr. Peter Wilden (Chairman of the Board of Directors) will assume the role of Executive Chairman with immediate effect.

Latest news about PolyPeptide Group AG

PolyPeptide Group AG Provides Earnings Guidance for 2024	Mar. 12	CI
Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024	Mar. 12
PolyPeptide Group Swings to Loss for FY23; Revenue Up	Mar. 12	MT
PolyPeptide Group AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
PolyPeptide Group Secures EUR111 Million Revolving Credit Facility	23-10-02	MT
Tech to the rescue	23-09-12
PolyPeptide Group AG Provides Earnings Guidance for the Year 2023	23-08-15	CI
Transcript : PolyPeptide Group AG, H1 2023 Earnings Call, Aug 15, 2023	23-08-15
PolyPeptide Appoints Lonza Executive as New CFO	23-08-15	MT
Polypeptide Group Posts H1 Loss; Revenue Down	23-08-15	MT
PolyPeptide Group AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines....	23-07-13
Transcript : PolyPeptide Group AG, Q2 2023 Earnings Call, Jul 13, 2023	23-07-13
Switzerland's PolyPeptide Forecasts Net Loss in FY23	23-07-13	MT
SIX Group Makes Index Adjustments Following Review	23-07-11	MT
PolyPeptide Signs Preferred Partner Collaboration Deal With Germany's Numaferm	23-05-10	MT
PolyPeptide and Numaferm Sign Preferred Partner Collaboration Agreement for Peptide Development and Production	23-05-09	CI
Global markets live: Lucid, Under Armour, Coty, PayPal, Western Digital...	23-05-09
PolyPeptide Moves, Expands French Innovation Lab	23-05-08	MT
Polypeptide Group AG Announces Chief Executive Officer Changes	23-04-04	CI
Polypeptide Group AG Announces Chief Financial Officer Changes	23-04-04	CI
PolyPeptide Group Appoints CEO, Interim CFO	23-04-03	MT
Transcript : PolyPeptide Group AG, 2022 Earnings Call, Mar 14, 2023	23-03-14
PolyPeptide Group Posts Lower FY22 Attributable Profit	23-03-14	MT
PolyPeptide Group AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI

Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Ratings for PolyPeptide Group AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

29.49 EUR

Average target price

22.24 EUR

Spread / Average Target

-24.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
POLYPEPTIDE GROUP AG	+64.67%	1.06B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals